Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas M Bridges

Showing results (61-70 of 108) with videos related to

Pageof 11
Sort By:
ACS Chemical Neuroscience|October 1, 2011
Discovery and characterization of novel subtype-selective allosteric agonists for the investigation of M(1) receptor function in the central nervous systemEvan P Lebois, Thomas M Bridges, L Michelle Lewis, et al.
Chemmedchem|April 3, 2014
Discovery, synthesis and characterization of a highly muscarinic acetylcholine receptor (mAChR)-selective M5-orthosteric antagonist, VU0488130 (ML381): a novel molecular probePatrick R Gentry, Masaya Kokubo, Thomas M Bridges, et al.
Bioorganic & Medicinal Chemistry Letters|June 29, 2012
Discovery of N-(4-methoxy-7-methylbenzo[d]thiazol-2-yl)isonicatinamide, ML293, as a novel, selective and brain penetrant positive allosteric modulator of the muscarinic 4 (M4) receptorJames M Salovich, Paige N Vinson, Douglas J Sheffler, et al.
Bioorganic & Medicinal Chemistry Letters|December 27, 2011
Development of a more highly selective M(1) antagonist from the continued optimization of the MLPCN Probe ML012Bruce J Melancon, Alexander P Lamers, Thomas M Bridges, et al.
The British Journal of Ophthalmology|May 11, 2021
Evaluation of intravitreal topotecan dose levels, toxicity and efficacy for retinoblastoma vitreous seeds: a preclinical and clinical studyCarley M Bogan, Jessica V Kaczmarek, Janene M Pierce, et al.
Chemistry (Weinheim an Der Bergstrasse, Germany)|January 17, 2019
Evaluation of 1,2,3-Triazoles as Amide Bioisosteres In Cystic Fibrosis Transmembrane Conductance Regulator Modulators VX-770 and VX-809Jake E Doiron, Christina A Le, Britton K Ody, et al.
Bioorganic & Medicinal Chemistry Letters|July 18, 2015
Further optimization of the mGlu5 PAM clinical candidate VU0409551/JNJ-46778212: Progress and challenges towards a back-up compoundYa Zhou, Chrysa Malosh, Susana Conde-Ceide, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 29, 2015
Allosteric activation of M4 muscarinic receptors improve behavioral and physiological alterations in early symptomatic YAC128 miceTristano Pancani, Daniel J Foster, Mark S Moehle, et al.
Bioorganic & Medicinal Chemistry Letters|October 28, 2021
Discovery of structurally distinct tricyclic M<sub>4</sub> positive allosteric modulator (PAM) chemotypes - Part 2Madeline F Long, Rory A Capstick, Paul K Spearing, et al.
Bioorganic & Medicinal Chemistry Letters|April 18, 2012
Continued optimization of the MLPCN probe ML071 into highly potent agonists of the hM1 muscarinic acetylcholine receptorBruce J Melancon, Rocco D Gogliotti, James C Tarr, et al.
Pageof 11

Showing results (61-70 of 108) with videos related to

Sort By:
Pageof 11
ACS Chemical Neuroscience|October 1, 2011
Discovery and characterization of novel subtype-selective allosteric agonists for the investigation of M(1) receptor function in the central nervous systemEvan P Lebois, Thomas M Bridges, L Michelle Lewis, et al.
Chemmedchem|April 3, 2014
Discovery, synthesis and characterization of a highly muscarinic acetylcholine receptor (mAChR)-selective M5-orthosteric antagonist, VU0488130 (ML381): a novel molecular probePatrick R Gentry, Masaya Kokubo, Thomas M Bridges, et al.
Bioorganic & Medicinal Chemistry Letters|June 29, 2012
Discovery of N-(4-methoxy-7-methylbenzo[d]thiazol-2-yl)isonicatinamide, ML293, as a novel, selective and brain penetrant positive allosteric modulator of the muscarinic 4 (M4) receptorJames M Salovich, Paige N Vinson, Douglas J Sheffler, et al.
Bioorganic & Medicinal Chemistry Letters|December 27, 2011
Development of a more highly selective M(1) antagonist from the continued optimization of the MLPCN Probe ML012Bruce J Melancon, Alexander P Lamers, Thomas M Bridges, et al.
The British Journal of Ophthalmology|May 11, 2021
Evaluation of intravitreal topotecan dose levels, toxicity and efficacy for retinoblastoma vitreous seeds: a preclinical and clinical studyCarley M Bogan, Jessica V Kaczmarek, Janene M Pierce, et al.
Chemistry (Weinheim an Der Bergstrasse, Germany)|January 17, 2019
Evaluation of 1,2,3-Triazoles as Amide Bioisosteres In Cystic Fibrosis Transmembrane Conductance Regulator Modulators VX-770 and VX-809Jake E Doiron, Christina A Le, Britton K Ody, et al.
Bioorganic & Medicinal Chemistry Letters|July 18, 2015
Further optimization of the mGlu5 PAM clinical candidate VU0409551/JNJ-46778212: Progress and challenges towards a back-up compoundYa Zhou, Chrysa Malosh, Susana Conde-Ceide, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 29, 2015
Allosteric activation of M4 muscarinic receptors improve behavioral and physiological alterations in early symptomatic YAC128 miceTristano Pancani, Daniel J Foster, Mark S Moehle, et al.
Bioorganic & Medicinal Chemistry Letters|October 28, 2021
Discovery of structurally distinct tricyclic M<sub>4</sub> positive allosteric modulator (PAM) chemotypes - Part 2Madeline F Long, Rory A Capstick, Paul K Spearing, et al.
Bioorganic & Medicinal Chemistry Letters|April 18, 2012
Continued optimization of the MLPCN probe ML071 into highly potent agonists of the hM1 muscarinic acetylcholine receptorBruce J Melancon, Rocco D Gogliotti, James C Tarr, et al.
Pageof 11